Pharmacoeconomics of combination antihypertensive therapy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.

Original languageEnglish
JournalBlood Pressure Monitoring
Volume6
Issue numberSUPPL. 1
StatePublished - 2001

Fingerprint

Pharmaceutical Economics
Health Care Costs
Antihypertensive Agents
Costs and Cost Analysis
Health Resources
Angiotensin Receptor Antagonists
Insurance Benefits
Drug Combinations
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Blood Pressure
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Pharmacoeconomics of combination antihypertensive therapy. / Hilleman, Daniel E.

In: Blood Pressure Monitoring, Vol. 6, No. SUPPL. 1, 2001.

Research output: Contribution to journalReview article

@article{23643e48542244239a324ae18edcebd0,
title = "Pharmacoeconomics of combination antihypertensive therapy",
abstract = "Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.",
author = "Hilleman, {Daniel E.}",
year = "2001",
language = "English",
volume = "6",
journal = "Blood Pressure Monitoring",
issn = "1359-5237",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Pharmacoeconomics of combination antihypertensive therapy

AU - Hilleman, Daniel E.

PY - 2001

Y1 - 2001

N2 - Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.

AB - Antihypertensive treatment should provide optimal health benefits while minimizing treatment costs. Most patients require a combination of drugs to achieve blood pressure goals. Two studies have shown that switching to fixed-dose combination therapy is effective, well tolerated, and cost-effective for most patients. A fixed-dose combination agent containing a diuretic and a β-blocker, an angiotensin-converting enzyme inhibitor, or an angiotensin II receptor antagonist is generally more effective, better tolerated, and does not cost more than the non-diuretic component. Therefore, the associated health-care resource costs of using these fixed-dose combination products should be less than those associated with the use of monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0035200252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035200252&partnerID=8YFLogxK

M3 - Review article

VL - 6

JO - Blood Pressure Monitoring

JF - Blood Pressure Monitoring

SN - 1359-5237

IS - SUPPL. 1

ER -